Market Place
Sourcing Support
Mindwalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results
12 Mar 2026 //
BUSSINESSWIRE
Mindwalk Holdings Corp. To Release Q3 FY2026 Financial Results
02 Mar 2026 //
BUSINESSWIRE
Mindwalk Advances Universal Influenza Program With Breakthrough
12 Jan 2026 //
PHARMIWEB
MindWalk Breakthrough Boosts Universal Flu Program
09 Jan 2026 //
BUSINESSWIRE
Mindwalk Reports Record Growth, Advances AI Asset Pipeline
15 Dec 2025 //
BUSINESSWIRE
Mindwalk Appoints R. Scott Areglado As CFO To Boost Growth
21 Oct 2025 //
BUSINESS WIRE
Mindwalk Appoints Dr. Thomas W. Lynch Chief Business Officer
15 Oct 2025 //
BUSINESSWIRE
Mindwalk Announces Share Repurchase Program
09 Oct 2025 //
BUSINESSWIRE
MindWalk Advances AI GLP-1 Program With Dual-Pathway Regimen
22 Sep 2025 //
BUSINESSWIRE
MindWalk Reports $7.6M Revenue, 45% Growth in Q2 Results
15 Sep 2025 //
BUSINESSWIRE
MindWalk Q1 2026 Results, Biz Highlights Coming Sept 15, 2025
10 Sep 2025 //
BUSINESSWIRE
ImmunoPrecise Transforms into MindWalk, Emphasizing AI Future
04 Sep 2025 //
FIERCE PHARMA
ImmunoPrecise Advances Universal Dengue Vaccine to Preclinical
27 Aug 2025 //
BUSINESSWIRE
ImmunoPrecise Sells Facilities to AVS Bio for AI Innovation
06 Aug 2025 //
BUSINESSWIRE
IPA Reports Record Q4 Revenue and Adjusted EBITDA for Fiscal 2025
29 Jul 2025 //
BUSINESSWIRE
ImmunoPrecise Adds Data Expert Jeff Fried to Advisory Board
21 Jul 2025 //
BUSINESSWIRE
ImmunoPrecise Complies with Nasdaq Minimum Bid Price Requirement
14 Jul 2025 //
BUSINESSWIRE
Industry Veteran Jon Lieber Joins ImmunoPrecise Antibodies Board
07 Jul 2025 //
BUSINESSWIRE
ImmunoPrecise Validates LENSai Epitope Mapping Platform
03 Jul 2025 //
BUSINESSWIRE
ImmunoPrecise Advances Dengue Vaccine With LENSai Platform
24 Jun 2025 //
BUSINESSWIRE
ImmunoPrecise Announces AI Breakthrough in Dengue Vaccine
05 Jun 2025 //
BUSINESSWIRE
ImmunoPrecise Antibodies Engages CORE IR for Investor Engagement
21 May 2025 //
BUSINESSWIRE
ImmunoPrecise Antibodies to Present at Maxim Group`s 2025 Virtual
20 May 2025 //
BUSINESSWIRE
IPA’s LENSai™ Delivers Fast, Gold-Standard Mapping
12 May 2025 //
BUSINESSWIRE
ImmunoPrecise Antibodies Aligns LENSai with FDA`s Non-Animal Test
11 Apr 2025 //
BUSINESSWIRE
ImmunoPrecise Antibodies Reports Q3 Fiscal Year 2025 Results
28 Mar 2025 //
BUSINESSWIRE
ImmunoPrecise Antibodies partners with biotech leader for cancer
13 Mar 2025 //
BUSINESSWIRE
IPA to Reschedule Q3 Financial Results to March 28, 2025
11 Mar 2025 //
BUSINESSWIRE
IPA To Report Q3 FY25 Results On March 13
05 Mar 2025 //
BUSINESSWIRE
ImmunoPrecise & RIBOPRO Partner for AI-Powered Antibody Discovery
26 Feb 2025 //
CONTRACTPHARMA
ImmunoPrecise Antibodies Announces Key Leadership Changes
24 Feb 2025 //
BUSINESSWIRE
ImmunoPrecise Moves To Nasdaq Capital, Gets Bid Price Extension
20 Feb 2025 //
BUSINESSWIRE
ImmunoPrecise Antibodies Shows Confidence with Share Purchases
23 Dec 2024 //
BUSINESSWIRE
ImmunoPrecise Reports Q2 FY2025 Results And Highlights
10 Dec 2024 //
BUSINESSWIRE
ImmunoPrecise to Host Techday on AI & Biologics Innovation
04 Nov 2024 //
BUSINESSWIRE
ImmunoPrecise Celebrates Nobel Prize Advances AI Protein Design
10 Oct 2024 //
BUSINESSWIRE
ImmunoPrecise Subsidiary Signs Agreement With Biotheus
02 Oct 2024 //
BUSINESSWIRE
ImmunoPrecise Advances Rabbit Antibody Developments
26 Sep 2024 //
BUSINESSWIRE
ImmunoPrecise Reports Q1 FY2025 Results
16 Sep 2024 //
BUSINESSWIRE
ImmunoPrecise Reports Q4 And Full Year 2024 Results
29 Jul 2024 //
BUSINESSWIRE
ImmunoPrecise Secures $3M Convertible Debenture Financing From Yorkville
16 Jul 2024 //
BUSINESSWIRE
BioStrand and PGxAI collaborate on AI model LENSai™ for pharmacogenomics
25 Jun 2024 //
BUSINESSWIRE
InterSystems and BioStrand Collab to Innovative Integration of Vector Search
28 Mar 2024 //
BUSINESSWIRE
ImmunoPrecise Antibodies Ltd. Second Quarter 2024 Earnings Release Call
27 Nov 2023 //
BUSINESSWIRE
ImmunoPrecise Antibodies Announces CFO Transition
19 Sep 2023 //
BUSINESSWIRE
ImmunoPrecise Antibodies Invites Investors to Interview with Market Radius
14 Jul 2023 //
BUSINESSWIRE
ImmunoPrecise Reports Financial Results for Full Fiscal Year 2023
07 Jul 2023 //
BUSINESSWIRE
Talem Enters into Collaboration and License Option Agreement with Astellas
30 Mar 2023 //
BUSINESSWIRE
Talem Announces a AI-Driven Antibody Discovery Collaboration with Libera Bio
15 Mar 2023 //
BUSINESSWIRE
ImmunoPrecise Antibodies Announces Voluntary Delisting from TSX Venture Exchange
22 Nov 2022 //
BUSINESSWIRE
IPA Reports Financial Results for First Quarter Fiscal Year 2023
14 Sep 2022 //
BUSINESSWIRE
NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity
14 Sep 2022 //
BUSINESSWIRE
Live Virus Assays Confirm PolyTope’s Efficacy Against SARS-CoV-2 Variants
29 Aug 2022 //
BUSINESSWIRE
ImmunoPrecise Reports Financial Results for Full Fiscal Year 2022
29 Jul 2022 //
BUSINESSWIRE
IPA to Report Financial Results for Q4 and Full FY 2022
26 Jul 2022 //
BUSINESSWIRE
Histopathology Data of PC Repeated Dose Toxicity Study and ex vivo TCR Analysis
12 Jul 2022 //
BUSINESSWIRE
IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery
14 Mar 2022 //
BUSINESSWIRE
IPA Updates on IND Enabling Program for PolyTope TATX-03
09 Mar 2022 //
BUSINESSWIRE
ImmunoPrecise Sets Q3 Fiscal 2022 Financial Results for March 16th
08 Mar 2022 //
BUSINESSWIRE
ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus
18 Jan 2022 //
BUSINESSWIRE
